Stock Track | ImmuneOnco Soars Over 26% as First Patient Dosed in Lupus Drug Trial

Stock Track10-25

Shares of ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG:1541) surged 26.28% on Thursday after the company announced a significant milestone in the clinical development of its lupus drug candidate, IMM0306.

According to a filing with the Hong Kong Stock Exchange, ImmuneOnco revealed that the first patient has been administered with a dose of IMM0306 in a Phase 1b clinical trial for the treatment of systemic lupus erythematosus (SLE). The drug is designed to target and bind to the proteins CD47 and CD20 found on cancerous B cells, with a stronger affinity for CD20. This targeted approach could potentially enhance the drug's effectiveness as a cancer treatment.

The positive clinical trial update was well-received by investors, driving ImmuneOnco's shares to close at HKD 7.25, up HKD 1.0 or 16.19% from the previous day's close. The market's enthusiasm reflects the promising prospects of IMM0306 as the company progresses its development for treating the autoimmune disease SLE.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1104722075?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-25 22:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104722075","market":"us","top_or_hot":-1,"title":"Stock Track | ImmuneOnco Soars Over 26% as First Patient Dosed in Lupus Drug Trial","media":"Stock Track","content":"<p>Shares of ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG:1541) surged 26.28% on Thursday after the company announced a significant milestone in the clinical development of its lupus drug candidate, IMM0306.</p>\n\n<p>According to a filing with the Hong Kong Stock Exchange, ImmuneOnco revealed that the first patient has been administered with a dose of IMM0306 in a Phase 1b clinical trial for the treatment of systemic lupus erythematosus (SLE). The drug is designed to target and bind to the proteins CD47 and CD20 found on cancerous B cells, with a stronger affinity for CD20. This targeted approach could potentially enhance the drug's effectiveness as a cancer treatment.</p>\n\n<p>The positive clinical trial update was well-received by investors, driving ImmuneOnco's shares to close at HKD 7.25, up HKD 1.0 or 16.19% from the previous day's close. The market's enthusiasm reflects the promising prospects of IMM0306 as the company progresses its development for treating the autoimmune disease SLE.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ImmuneOnco Soars Over 26% as First Patient Dosed in Lupus Drug Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ImmuneOnco Soars Over 26% as First Patient Dosed in Lupus Drug Trial\n</h2>\n\n<h4 class=\"meta\">\n\n2024-10-25 22:10 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG:1541) surged 26.28% on Thursday after the company announced a significant milestone in the clinical development of its lupus drug ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01541","symbol_name":"宜明昂科-B","start_time":0,"source_url":"","article_id":"1104722075","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104722075","pubTimestamp":1729865451,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of ImmuneOnco Biopharmaceuticals  Co., Ltd.  surged 26.28% on Thursday after the company announced a significant milestone in the clinical development of its lupus drug candidate, IMM0306.According to a filing with the Hong Kong Stock Exchange, ImmuneOnco revealed that the first patient has been administered with a dose of IMM0306 in a Phase 1b clinical trial for the treatment of systemic lupus erythematosus . The drug is designed to target and bind to the proteins CD47 and CD20 found on ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01541":"宜明昂科-B"},"translate_title":"股票追踪ImmuneOnco股价飙升超过26%，成为狼疮药物试验中第一位接受剂量的患者","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1},"content_text":"Shares of ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG:1541) surged 26.28% on Thursday after the company announced a significant milestone in the clinical development of its lupus drug candidate, IMM0306.\nAccording to a filing with the Hong Kong Stock Exchange, ImmuneOnco revealed that the first patient has been administered with a dose of IMM0306 in a Phase 1b clinical trial for the treatment of systemic lupus erythematosus (SLE). The drug is designed to target and bind to the proteins CD47 and CD20 found on cancerous B cells, with a stronger affinity for CD20. This targeted approach could potentially enhance the drug's effectiveness as a cancer treatment.\nThe positive clinical trial update was well-received by investors, driving ImmuneOnco's shares to close at HKD 7.25, up HKD 1.0 or 16.19% from the previous day's close. The market's enthusiasm reflects the promising prospects of IMM0306 as the company progresses its development for treating the autoimmune disease SLE.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1104722075"}